What Merida’s precision antibody-degradation platform reveals about the new economics of biotech M&A—and why Big Pharma is increasingly paying for platform optionality, time and the right to be early.
On August 31, 2026, Eli Lilly announced a definitive agreement to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and contingent milestone payments. The transaction is expected to close in the fourth quarter of 2026, subject to customary closing conditions and regulatory approvals.
At first glance, the transaction looks aggressive.
Merida launched in April 2025 with a $121 million Series A. Its lead program, MER511, is still in Phase 1 development for Graves’ disease and thyroid eye disease (TED). The company has no commercial product and limited clinical validation.
So why would one of the world’s largest pharmaceutical companies commit up to nearly $3 billion to a company at such an early stage?
The answer is unlikely to be found in MER511 alone.
The more interesting explanation is that Lilly is buying an option on a new therapeutic platform.
And that distinction matters.
The next generation of biotech M&A may increasingly be about acquiring the ability to create multiple future products—not simply buying the next product.
That is the deeper significance of the Merida transaction.
1. The Headline Number Is Not the Real Story
The headline is simple:
Eli Lilly → Merida Biosciences → up to $2.875 billion
But the strategic logic is considerably more interesting.
Merida is developing engineered biologics designed to selectively target and eliminate pathogenic antibodies associated with autoimmune and allergic diseases, rather than broadly suppressing immune function. Its platform is designed around selective binding, clearance and durable reduction of disease-driving antibodies and their sources.
The lead program, MER511, is being evaluated in a Phase 1 study for Graves’ disease and TED. Merida’s pipeline also includes MER769, an IgE-directed program in IND-enabling studies for food allergy, asthma, chronic spontaneous urticaria and other allergic diseases, as well as MER683 for primary membranous nephropathy and other discovery-stage programs.
This changes the valuation question.
A conventional single-asset acquisition might be framed as:
One drug → One indication → One market
A platform acquisition can instead be framed as:
One biological principle → Multiple targets → Multiple diseases → Multiple products
That is where strategic value begins to compound.
Lilly is therefore not simply buying the future cash flows of MER511.
It is buying the possibility that MER511 becomes the first clinical validation point for a much broader technology platform.
2. From Asset Value to Platform Value
Traditional biotech valuation often begins with the lead asset.
Analysts model:
- probability of clinical success;
- addressable patient population;
- potential pricing;
- market share;
- development costs;
- regulatory probability;
- time to commercialization;
- and future cash flows.
All of these remain essential.
But they do not necessarily capture the full value of a platform company.
Consider the difference between two companies.
Company A
Has one promising Phase 1 drug.
If that drug succeeds, the company has a valuable product.
Company B
Has a technology capable of generating multiple drugs, with its first clinical program providing an early test of the underlying mechanism.
If the first program succeeds, the value of the company may rise not only because Drug #1 becomes more valuable, but because confidence in Drug #2, Drug #3 and future programs rises simultaneously.
This is the essence of platform optionality.
At OP-MA, we frame this through three layers of biotech M&A value:
Layer 1 — Asset Value
What can the lead program become?
Layer 2 — Platform Value
What additional products can the underlying technology create?
Layer 3 — Strategic Option Value
What future opportunities does ownership give the acquirer?
The distinction is crucial because an acquirer may be paying for all three layers simultaneously.
The lead asset may be the proof point. The platform is the option. The strategic value is what the buyer can do with that option.
Merida is particularly interesting because the company itself describes its discovery engine as potentially applicable to more than two dozen autoimmune and allergic diseases driven by pathogenic antibodies. That does not mean all of those opportunities will become successful products. It does, however, illustrate why the strategic valuation of a platform can exceed the standalone value of its lead program.
3. What Lilly Actually Bought
The scientific proposition behind Merida is straightforward to describe, even if proving it clinically is considerably harder.
Many autoimmune therapies work by suppressing or modulating components of the immune system.
Merida is pursuing a more targeted approach: identify disease-driving antibodies and selectively eliminate them while seeking to preserve protective immune function. Its platform uses engineered Fc biotherapeutics intended to direct targeted antibodies toward endogenous clearance mechanisms and, according to Merida, can also inhibit the B cells responsible for producing those pathogenic antibodies.
For Graves’ disease, the target is particularly clear.
Pathogenic thyroid-stimulating antibodies activate the thyroid-stimulating hormone receptor and contribute to the disease. MER511 is designed to selectively target those antibodies and their B-cell sources.
That gives the program an important strategic characteristic:
The therapeutic mechanism is closely connected to the biological driver of disease.
If that approach proves clinically effective, Lilly could potentially apply the underlying technology beyond Graves’ disease.
That is fundamentally different from buying a conventional molecule whose commercial opportunity is largely defined by a single indication.
The strategic question becomes:
What happens to the value of the platform if the first clinical experiment works?
That is a much larger question than:
“What is MER511 worth today?”
4. Why Buy at Phase 1?
This may be the most important M&A question raised by the transaction.
If Lilly wanted only a de-risked asset, it could wait.
But waiting has a cost.
By the time a promising biotech reaches Phase 2 or Phase 3:
- clinical uncertainty may have fallen;
- the valuation may have increased;
- competing buyers have more information;
- additional strategic bidders may appear;
- and the asset may become considerably more expensive.
The buyer is therefore forced to choose between two forms of uncertainty.
Buy early
Pay less today, but accept more scientific risk.
Buy later
Reduce scientific uncertainty, but potentially pay a much higher strategic price.
Lilly appears to have chosen the first approach with Merida.
That is classic real-options logic.
At an early stage, uncertainty is high.
But so is the range of possible future outcomes.
If the technology fails, the expected value of further development falls.
If it succeeds, the value of the platform, pipeline and strategic position can rise simultaneously.
The acquisition therefore gives Lilly something more valuable than simply a Phase 1 asset:
the right to participate in the upside before the market has fully resolved the uncertainty.
This is where Time-to-Value becomes relevant.
Lilly is not necessarily buying a guaranteed faster approval.
It is buying earlier ownership, earlier control and earlier access to the development opportunity.
5. The Time Premium in Biotech M&A
At OP-MA, we have argued that time itself can become a component of M&A value.
For a pharmaceutical company, time has several dimensions.
Clinical Time
How quickly can the asset generate the next meaningful data point?
Regulatory Time
How quickly can the program move through development and toward approval?
Commercial Time
How quickly can the product contribute to a future franchise?
Competitive Time
How long before competitors acquire or develop similar technology?
Strategic Time
How quickly can the buyer establish a position in an emerging therapeutic category?
Platform Time
How quickly can the buyer begin applying the underlying technology to additional programs?
The Merida transaction is interesting because several of these clocks begin running simultaneously.
The lead asset is already in Phase 1.
The platform already has additional development programs.
The buyer can bring substantial clinical-development infrastructure to the company.
And ownership gives Lilly control over how quickly the technology can be expanded.
This is why we believe the economics of early-stage biotech M&A should increasingly be viewed through a Time-to-Value lens.
The value of an acquisition is not only what the asset is worth today. It is also how much strategic time the acquisition gives the buyer.
6. From Proof-of-Concept Premium to Platform Premium
This transaction also connects to a broader shift in biotech valuation.
In our previous analysis of biotech financing, we examined the Proof-of-Concept Premium: the disproportionate increase in value that can occur when early scientific uncertainty is replaced by credible human data.
Merida suggests another step in that progression.
The value curve can be thought of as:
Scientific Hypothesis
↓
Proof of Concept
↓
Validated Mechanism
↓
Validated Platform
↓
Multiple Commercial Opportunities
The critical point is that this curve is not necessarily linear.
If one drug succeeds, the value of that drug rises.
But if the underlying mechanism is validated across multiple programs, the valuation of the entire platform can re-rate.
That is the difference between:
Product Premium
and
Platform Premium
A product can generate revenue.
A platform can potentially generate a pipeline.
And a strategic buyer can value the right to control that pipeline before every future asset exists.
7. Why the “Second Drug” May Matter More Than the First
This is one of the most important implications for biotech valuation.
Imagine that an acquirer evaluates MER511 purely through a risk-adjusted net present value framework.
The result would depend heavily on the probability of success of the lead program.
But imagine that the lead program also functions as a validation experiment for the underlying technology.
If successful, it could increase confidence in:
- MER769;
- MER683;
- additional antibody-driven autoimmune programs;
- additional allergic-disease programs;
- and future discovery programs not yet clinically defined.
The first asset therefore has two jobs.
Job 1
Become a successful medicine.
Job 2
Validate the underlying technology.
That second function can create substantial strategic value.
The first clinical asset can serve as proof of the platform rather than simply as a product.
This is why a platform-stage acquisition can appear expensive when viewed through a single-asset valuation lens while remaining strategically rational for a buyer with the resources to exploit the broader opportunity.
8. Lilly’s Position Changes the Economics
Lilly is in an unusually strong position to make this type of investment.
Its major metabolic franchises have created substantial financial resources and a powerful growth engine. At the same time, Lilly has been expanding beyond its traditional metabolic focus into areas including immunology, neuroscience and oncology. Its Merida announcement specifically described the acquisition as strengthening Lilly’s immunology capabilities.
That creates an important asymmetry.
For a venture-backed biotech:
Scientific uncertainty can threaten survival.
For a large pharmaceutical company:
Scientific uncertainty can become an investment variable.
Lilly has:
- capital;
- clinical-development infrastructure;
- regulatory expertise;
- manufacturing capabilities;
- global commercial resources;
- and the ability to run multiple development programs simultaneously.
The strategic question is therefore not:
“Is Merida already de-risked?”
It clearly is not.
The more relevant question is:
“Is the potential strategic upside large enough to justify owning the technology before the uncertainty is resolved?”
That is a fundamentally different M&A philosophy.
9. Deal Structure: Paying for Upside Without Paying for All of It Today
The structure of the transaction is itself informative.
Lilly will pay up to $2.875 billion in cash, inclusive of an upfront payment and contingent milestone payments. The upfront amount has not been publicly disclosed.
That distinction matters.
The headline figure is not the same thing as cash paid at closing.
For an early-stage biotech, contingent consideration can serve as a bridge between today’s uncertainty and tomorrow’s validation.
For the buyer
Milestones reduce the amount of capital committed before important value inflection points.
For the seller
Milestones preserve participation in future upside if the technology delivers.
For investors
The structure creates a mechanism for translating scientific progress into additional transaction value.
This is particularly relevant to platform acquisitions.
The buyer does not have to pay the entire future valuation before the future exists.
The seller, meanwhile, can negotiate for meaningful upside if the platform achieves defined milestones.
In other words:
The deal structure allocates scientific risk between buyer and seller.
For biotech founders negotiating with strategic buyers, that distinction is critical.
A headline transaction value may attract attention.
But the real economic questions are:
- How much is paid upfront?
- Which milestones trigger additional payments?
- Who controls development?
- How achievable are the milestones?
- What happens if the buyer changes development priorities?
- How are future indications treated?
- What happens to assets outside the initial transaction thesis?
The headline number is only the beginning of the negotiation.
10. What Merida’s Investors Actually Demonstrated
Merida’s financing history is also instructive.
The company launched in April 2025 with a $121 million Series A, co-led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, with participation from GV and Perceptive Xontogeny Venture Funds.
Roughly sixteen months later, the company announced an acquisition agreement carrying a maximum consideration of up to $2.875 billion.
That does not mean investors simply achieved a 20-plus-fold return on the $121 million financing. Ownership percentages, subsequent dilution, transaction structure and milestone realization all matter.
But the strategic sequence is powerful:
Capital
→
Platform Creation
→
Clinical Validation
→
Strategic Buyer
→
Potential Platform-Scale Exit
This is an increasingly important venture model.
The objective is not necessarily to independently develop every potential indication through commercialization.
It can be to create enough evidence that a strategic buyer recognizes the value of the underlying platform and has a stronger ability to monetize it.
11. The Competitive Landscape Matters—but It Is Not the Whole Story
Merida’s lead program enters an established therapeutic environment.
Graves’ disease and TED already have approved treatments, meaning MER511 will not enter a market without precedent.
That actually makes the acquisition more interesting from an M&A perspective.
Lilly is not buying a technology because there is no market.
It is buying a technology that may potentially change how an existing biological problem is addressed.
The distinction matters.
In a completely unvalidated disease area, a platform must prove both:
- that the biological mechanism works; and
- that the market exists.
In an established disease area, the commercial need is easier to understand.
The strategic uncertainty becomes more concentrated around:
Can the new mechanism deliver a meaningful improvement over existing approaches?
That is a much more attractive question for a large pharmaceutical company capable of funding the necessary clinical experiments.
12. What This Means for Biotech Founders
The Merida transaction offers a powerful lesson for founders.
Do not ask only:
“How large is our lead asset?”
Ask:
“If our lead asset works, what else becomes possible?”
That second question can materially change how a company should build its M&A narrative.
A conventional pipeline presentation might say:
Program A → Phase 1
Program B → Preclinical
Program C → Discovery
A platform-oriented narrative says something different:
Program A validates the mechanism.
Program B demonstrates transferability.
Program C expands the addressable market.
This is strategically more powerful.
The buyer is no longer looking at three separate assets.
The buyer is looking at:
one technology generating multiple options.
That is platform value.
13. The Implication for Licensing and Cross-Border Biotech
The Merida case also has implications beyond US biotech.
For Japanese, European, Australian and Chinese biotech companies seeking strategic partners, the objective should not always be to maximize the first upfront payment.
Sometimes the more valuable partner is the one capable of accelerating validation.
A strong pharmaceutical partner can provide:
Capital + Clinical Development + Regulatory Expertise + Manufacturing + Commercial Validation
But there is another potential benefit:
M&A Optionality
A licensing transaction can give a large pharmaceutical company the opportunity to learn about an asset before deciding whether to acquire the entire company.
This creates a potential strategic sequence:
License-Out
↓
Clinical Validation
↓
Strategic Investment / Partnership
↓
Global Rights Expansion
↓
Acquisition
Not every license becomes an acquisition.
But the logic is increasingly relevant to cross-border biotech strategy.
A licensing transaction is not necessarily the exit. It can be the first step in creating an informed acquisition option.
For companies outside the major pharmaceutical markets, this is an important change in how BD strategy should be designed.
14. The New Biotech M&A Equation
The Merida transaction allows us to extend the way biotech companies are valued.
A conventional approach asks:
What is the expected value of the pipeline?
A strategic M&A approach asks three additional questions:
1. Platform Optionality
How many additional products can the technology potentially generate?
2. Time Advantage
How much earlier can the buyer act by acquiring rather than developing internally or waiting for later validation?
3. Strategic Optionality
What future decisions become available to the buyer once it owns the platform?
At OP-MA, we summarize this as:
Strategic Biotech Value = Current Pipeline + Platform Optionality + Time Advantage
This is not intended as a literal valuation formula.
It is a framework for understanding why strategic buyers can rationally pay more than a conventional standalone-asset valuation might suggest.
The acquisition premium can reflect not only expected cash flows, but also the value of future choices.
15. From Buying Drugs to Buying the Ability to Create Drugs
This may ultimately be the most important message from Lilly’s Merida acquisition.
For decades, pharmaceutical M&A has often been framed around the search for the next blockbuster.
That logic remains important.
But platform acquisitions introduce another question:
What technology gives the buyer the ability to create several future blockbusters?
That is a fundamentally different strategic proposition.
A successful drug produces revenue.
A successful platform can produce a pipeline.
A platform combined with a large pharmaceutical company’s capital, development infrastructure and global commercial capabilities can potentially produce an entire franchise.
That is why platform optionality can command a premium.
And that premium becomes particularly powerful when the buyer has the balance sheet and organizational capacity to exploit it.
16. The Real Strategic Asset: The Right to Be Early
The Merida transaction ultimately brings together three ideas.
Platform
Lilly is acquiring a technology with potential applications beyond the lead program.
Time
Lilly gains immediate ownership and control rather than waiting for the market to validate every future opportunity.
Optionality
If the underlying mechanism succeeds, Lilly can potentially expand the technology across additional diseases and programs.
This produces what we believe is an increasingly important form of M&A value:
The right to be early.
Being early has economic value when:
- the technology is scarce;
- the platform has multiple potential applications;
- the buyer has the capability to accelerate development;
- later-stage validation could materially increase the price;
- and competitors could otherwise acquire the same strategic position.
That is the deeper economic logic behind many early-stage strategic acquisitions.
Conclusion: The Next M&A Premium May Belong to Platforms
The most important feature of Eli Lilly’s proposed acquisition of Merida Biosciences is not the $2.875 billion headline.
It is the stage at which Lilly is willing to make the investment.
Merida’s lead program remains in Phase 1.
Yet Lilly is prepared to acquire the company because the strategic value may extend beyond the lead drug to the underlying platform, its future pipeline and the time gained by owning the technology now. The transaction structure also allows future value to remain linked to clinical and other milestones.
That points to a broader evolution in biotech M&A.
The old question was:
“What is the next blockbuster drug?”
The new question may increasingly be:
“What platform gives us the ability to create the next several blockbuster drugs?”
That is the shift from asset value to platform value.
And beyond platform value lies something even more strategic:
the value of time, optionality and the right to be early.
The Merida transaction therefore supports a broader OP-MA thesis:
Big Pharma is moving from buying products to buying platforms, from buying revenue to buying optionality, and from paying only for certainty to paying for the right to be early.
For biotech founders, the implication is equally clear.
The value of a company is not determined only by what its lead program can become.
It is also determined by:
what else becomes possible if that program works.
That is the essence of Platform Optionality.
And as pharmaceutical companies compete for the technologies that could define the next decade of medicine, the next M&A premium may not belong to the company with the most advanced drug.
It may belong to the company with the platform that gives the buyer the most future choices—and the fastest path to exploiting them.
OP-MA Framework
Asset Value
What can the lead program become?
Platform Value
What additional products can the technology create?
Time Advantage
How much earlier can the buyer act?
Strategic Option Value
What future opportunities become available through ownership?
Strategic Biotech Value = Current Pipeline + Platform Optionality + Time Advantage
The framework is conceptual rather than a literal valuation equation. Actual transaction value depends on clinical probability, commercial opportunity, intellectual property, competitive dynamics, deal structure and other factors.
Sources
Primary transaction and company information: Eli Lilly and Company; Merida Biosciences. Merida’s April 2025 launch announcement documents its $121 million Series A financing, while the August 31, 2026 transaction announcement documents the proposed acquisition value, consideration structure, advisors and expected closing timeline.
Merida’s current pipeline and platform descriptions provide the latest information on MER511, MER769, MER683 and its precision antibody-degradation approach.
Independent reporting on the transaction and its strategic context: Reuters.
For the primary company disclosures, see Eli Lilly Investor Relations and Merida Biosciences.